Kangchen Pharmaceutical (1681.HK): Significant advantages in the field of nephrology, performance continues to grow rapidly
Kangchen Pharmaceutical (1681.HK): Continued rapid growth in the field of nephrology
Kangchen Pharmaceutical (1681.HK): Deeply involved in the field of nephrology, rapid profit growth
Kangson Pharmaceutical (01681.HK): Annual performance is impressive, and the field of nephrology is developing in depth
Kangson Pharmaceutical (1681.HK): Deepening the field of nephropathy with continuous improvement in operating efficiency
Kangson Pharmaceutical (01681.HK): Steady revenue growth under the pandemic continues to deepen the nephrology sector
Kangson Pharmaceutical (1681.HK): The leading position in the nephrology field is stable and the performance is growing rapidly
Kangson Pharmaceutical (01681.HK): Annual performance was steady and the reform of Jade Pharmaceutical progressed smoothly
Kangson Pharmaceutical (1681.HK): Yulin Pharmaceutical's 21-year performance improvement trend has not changed
Kangson Pharmaceutical (01681.HK): The next catalyst: Yulin Pharmaceutical is expected to improve in 2021
Kangson Pharmaceutical (01681.HK): Jade Pharmaceutical's rectification effects are initially showing, and it is expected that it will usher in an inflection point in performance
Kangson Pharmaceutical (01681.HK): As the effects of the Jade Pharmaceutical marketing reform gradually became apparent, it is expected to usher in an inflection point in performance
Kangson Pharmaceutical (1681.HK): Down to earth and moving forward steadily
[Smart Investment] Kangson Pharmaceutical (1681.HK): 2018 performance is in line with expectations; valuation is underestimated
Kangson Pharmaceutical (1681.HK) Interim Report Review: The results for the first half of the year were in line with expectations
Kangchen Pharmaceutical (1681.HK): Yulin Pharmaceutical is still the driving Force of growth
Kangson Pharmaceutical (01681.HK): Yulin Company's reforms have achieved remarkable results, and many powerful varieties are ready to go
Kangchen Pharmaceutical (1681.HK): high growth prospects clear; valuation attractive
Kangchen Pharmaceutical (1681.HK): An underrated manufacturer of proprietary Chinese medicines
Kangson Pharmaceutical (1681.HK): Traditional Brand Recovery
No Data